Allergon AB

Company snapshot

Allergon is a world leader in the research and manufacturing of allergen source materials, used in the diagnosis and treatment of allergies.

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 24 US patent(s) indexed to this assignee profile.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Allergon AB. Not investment advice.

• What is Allergon AB?

  Allergen is a pharma organization headquartered in JP. Primary therapeutic focus areas include Birch Pollen-induced Allergic Rhinoconjunctivitis. NovaPharmaNews links 1 clinical program(s), 3 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTri

• Is Allergon AB publicly traded?

  Allergon AB appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Allergon AB develop or market?

  We link 6 drug profile(s) where Allergon AB is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/stallergenes#company-drugs.

• What are the latest developments for Allergon AB?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Allergon AB focus on?

  Allergon AB focuses on Birch Pollen-induced Allergic Rhinoconjunctivitis based on our analysis of their pipeline programs and drug development activities.